FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998476075> ?p ?o ?g. }

• W1998476075 endingPage "e357" @default.
• W1998476075 startingPage "e356" @default.
• W1998476075 abstract "We thank Richman et al for their interest in our work and provision of additional pharmacogenetic data from patients included in the FOCUS (Fluorouracil [FU], Oxaliplatin and CPT11 [irinotecan]: Use and Sequencing) trial. Of the 2,135 patients enrolled onto the FOCUS trial—in which one of three patients was randomly assigned to receive first-line FU alone and one of six to receive first-line FU plus oxaliplatin—the authors analyzed TS-5 UTR polymorphism in 938 patients (44%) for whom DNA was available. First, they saw no effect on overall survival, which is in accordance with our results. Second, in 910 patients (43%) with complete data, the authors showed a prognostic effect of the polymorphism on progression-free survival (PFS), the 2R allele being protective, whereas in the FFCD (Federation Francophone de la Cancerologie Digestive) 2000-05 trial, we saw no overall prognostic effect on PFS. However, this effect was weak (perallele hazard ratio [HR], 0.9; 95% CI, 0.82 to 0.99; P .03). Third, they failed to validate our finding that genotyping of TS-5 UTR may be a valuable tool in identifying patients who will and will not benefit from first-line combination therapy. This was mainly because of the observed results in patients with 3R/3R genotype (HR for PFS with first-line FU plus oxaliplatin v FU alone, 0.68; 95% CI, 0.48 to 0.96, in FOCUS trial compared with HR, 0.96; 95% CI, 0.66 to 1.40 in FFCD 2000-05 trial). However, it is not possible to assert that the results of the two trials are discordant, because of the large overlap of the CIs (Fig 1). This was confirmed by the absence of significant heterogeneity between the two trials. Furthermore, we pooled the results of the two trials. A significant trend (P .02) was observed between TS-5 UTR genotype and treatment effect on PFS. The addition of oxaliplatin to first-line FU had no significant impact on PFS in patients with the 3R/3R genotype (HR, 0.80; 95% CI, 0.62 to 1.03). We have no clear explanation for the differences observed between the pharmacogenetic analyses in the FOCUS and FFCD 2000-05 trials. In particular, we do not know whether these differences may be the result of differences in FU dosage (2,400 mg/m in FFCD 2000-05 trial v 2,800 mg/m in FOCUS trial), oxaliplatin dosage (100 mg/m v 85 mg/m), prior history of adjuvant FU-based chemotherapy (11% v 23% to 27%), number of disease sites (single-disease site, 52% v 29% to 36%), tumor assessment periodicity (every 8 weeks v 12 weeks), or pattern of DNA extraction (blood v normal bowel mucosa; normal tissue not available in 25% of patients in pharmacogenetic analysis of FOCUS trial). In conclusion, because the FOCUS pharmacogenetic analysis failed to validate our results, additional large prospective studies are mandatory to determine definitively the predictive impact of TS-5 UTR genotype and the effect (or absence of effect) on PFS of the addition of oxaliplatin to FU in 3R/3R patients." @default.
• W1998476075 created "2016-06-24" @default.
• W1998476075 creator A5017132355 @default.
• W1998476075 creator A5041492973 @default.
• W1998476075 creator A5043053032 @default.
• W1998476075 creator A5089818289 @default.
• W1998476075 date "2011-04-20" @default.
• W1998476075 modified "2023-10-18" @default.
• W1998476075 title "Reply to S.D. Richman et al" @default.
• W1998476075 cites W2032367730 @default.
• W1998476075 cites W2138849304 @default.
• W1998476075 cites W2151158169 @default.
• W1998476075 doi "https://doi.org/10.1200/jco.2010.34.1503" @default.
• W1998476075 hasPublicationYear "2011" @default.
• W1998476075 type Work @default.
• W1998476075 sameAs 1998476075 @default.
• W1998476075 citedByCount "1" @default.
• W1998476075 crossrefType "journal-article" @default.
• W1998476075 hasAuthorship W1998476075A5017132355 @default.
• W1998476075 hasAuthorship W1998476075A5041492973 @default.
• W1998476075 hasAuthorship W1998476075A5043053032 @default.
• W1998476075 hasAuthorship W1998476075A5089818289 @default.
• W1998476075 hasBestOaLocation W19984760751 @default.
• W1998476075 hasConcept C71924100 @default.
• W1998476075 hasConceptScore W1998476075C71924100 @default.
• W1998476075 hasIssue "12" @default.
• W1998476075 hasLocation W19984760751 @default.
• W1998476075 hasOpenAccess W1998476075 @default.
• W1998476075 hasPrimaryLocation W19984760751 @default.
• W1998476075 hasRelatedWork W1489783725 @default.
• W1998476075 hasRelatedWork W1506200166 @default.
• W1998476075 hasRelatedWork W2039318446 @default.
• W1998476075 hasRelatedWork W2048182022 @default.
• W1998476075 hasRelatedWork W2080531066 @default.
• W1998476075 hasRelatedWork W2604872355 @default.
• W1998476075 hasRelatedWork W2748952813 @default.
• W1998476075 hasRelatedWork W2899084033 @default.
• W1998476075 hasRelatedWork W3032375762 @default.
• W1998476075 hasRelatedWork W3108674512 @default.
• W1998476075 hasVolume "29" @default.
• W1998476075 isParatext "false" @default.
• W1998476075 isRetracted "false" @default.
• W1998476075 magId "1998476075" @default.
• W1998476075 workType "article" @default.